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It’s	unclear	whether	disease-modifying	
antirheumatic	agents	(DmArDs)	as	first-line	
therapy	in	nonrheumatoid	rheumatologic	
diseases	are	effective	because	the	question	
has	not	been	studied.	As	second-line	
therapy,	the	use	of	some	DmArDs	appears	
to	be	beneficial	for	patients	with	psoriatic	
arthritis	(strength	of	recommendation	
[sor]:	A,	based	on	systematic	reviews	of	
good-quality	randomized	controlled	trials)	
and	ankylosing	spondylitis	(sor:	B,	based	
on	systematic	reviews	of	moderate	quality	
trials).	Data	on	the	safety	and	efficacy	of	
DmArDs	as	second-line	therapy	for	other	
arthritic	conditions	is	limited	(sor:	C,	
based	on	small	prospective	cohort	trials).
There are many options,  
but remember the risks
Traditionally,	nonsteroidal	anti-inflammatory	
agents	(NsAIDs)	have	been	the	mainstay	of	
treatment	for	rheumatologic	disorders	other	
than	rheumatoid	arthritis.	methotrexate	has	
been	used	in	psoriatic	arthritis	because	it	
also	controls	the	skin	disorder;	sulfasalazine	
has	been	used	in	arthritis	associated	with	
inflammatory	bowel	disease,	as	it	helps	the	
bowel	disorder	itself.	However,	little	evidence	
shows	a	definitive	benefit	for	the	arthritis.	
	 The	advent	of	tumor	necrosis	factor	
(TNF)	blockers	has	changed	the	direction	
of	research	in	this	area;	these	agents	are	
being	used	more	and	more	in	inflammatory	
arthritides.	While	staying	up	to	date	on	the	
TNF	antagonists,	it’s	important	to	remember	
the	complications	associated	with	them—
particularly	the	increased	risk	of	infections	
and	increased	propensity	for	neoplastic	
disorders.	Consider	those	on	TNF	blockers	
as	relatively	immunosuppressed	(number	
needed	to	harm	[NNH]=59	for	infection	and	
154	for	malignancy).1
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z 	Evidence summary
The use of DMARDs has become stan-
dard of care for rheumatoid arthritis, for 
both therapy and prevention of progres-
sion of this debilitating disease. How-
ever, the use of DMARDs in nonrheu-
matoid rheumatologic disease is still un-
der investigation, and at this point, the 
use of DMARDs as first-line therapy is 
not recommended; however, second-line 
therapy with DMARDs is common.
For psoriatic arthritis, DMARDs are 
beneficial as a second-line therapy
A Cochrane systematic review identified 
13 randomized controlled trials enrolling 
Clinical commentary
Evidence-based answer Psoriatic arthritis affecting  
the joints and nails
fast track
As second-line 
therapy, some 
DMARDs benefit 
patients with  
psoriatic arthritis 
and ankylosing  
spondylitis
fast track
934 vol	56,	No	11	/	November	2007		ThE JournAl of fAmily PrACTiCE
C
l
in
iC
a
l
 I
N
q
u
Ir
Ie
s
a combined 1022 patients with psoriatic 
arthritis randomly assigned to receive 
a DMARD—methotrexate, sulfasala-
zine (Azulfidine), azathioprine (Imuran/ 
Azasan), or etretinate (Tegison; no lon-
ger available in the US)—compared with 
placebo.2 All agents were better than pla-
cebo; however, only 2 agents (parenteral 
high-dose methotrexate and sulfasala-
zine) had clinically important benefits for 
more than half the patients. The studies 
were too small to establish toxicity or to 
evaluate the other agents. 
nSAiDs are still the preferred first-line 
therapy, concluded a recent publication on 
the treatment of psoriatic arthritis, which 
looked at 54 different studies; however, 
second-line therapy could include metho-
trexate, sulfasalazine, etanercept (Enbrel), 
infliximab (Remicade), cyclosporine, 
or combination therapy.3 Sulfasalazine 
appeared to be clinically beneficial for 
peripheral psoriatic arthritis. 
Etanercept vs placebo. An initial 
study (60 patients) of etanercept vs pla-
cebo among patients who were permit-
ted to stay on methotrexate or predni-
sone showed a response rate of 87% vs 
23% (P<.0001; number needed to treat 
[NNT]=1.56).4 
infliximab vs placebo. A study of 
infliximab vs placebo involving 104 
patients had similar results, with good 
response in 65% vs 10% (NNT=1.81) 
at 16 weeks; infliximab also inhibited 
radiographic progression by 22%.5 
Cyclosporine. Although it is effective, 
reserve cyclosporine for patients who do 
not improve on other regimens, because 
of its nephrotoxicity.3 
DMARDs show some benefit  
in treating ankylosing spondylitis
Two recent Cochrane systematic reviews 
on ankylosing spondylitis examined the 
use of sulfasalazine and methotrexate as 
second-line agents.6,7 Eleven trials were 
included in the sulfasalazine analysis, 
with a total of 895 patients. Sulfasalazine 
demonstrated some benefit in reducing 
erythrocyte sedimentation rates (ESRs) 
and morning stiffness, but there was 
no evidence that the drug reduced pain 
or improved physical function, spinal 
mobility, or rate of enthesitis. Sulfasala-
zine was well tolerated and may be use-
ful in early mild disease for patients 
with peripheral arthritis and high ESRs. 
On the other hand, evidence was insuf-
ficient to determine whether methotrex-
ate benefited patients with ankylosing 
spondylitis. 
in other trials, infliximab and etaner-
cept showed good potential for benefit in 
treating ankylosing spondylitis. 
One study of infliximab vs placebo 
showed 61.2% vs 19.2% patients with 
good clinical benefit at 24 weeks and 
only mild or moderate adverse events 
(P<.001; NNT=2.38).8 
Similarly, a smaller study (84 pa-
tients) showed that 60% of patients on 
etanercept vs 20% on placebo had good 
clinical benefit at only 12 weeks (P<.001, 
NNT=2.5).9 
For other rheumatic diseases, 
studies are mixed
Due to cyclosporine’s toxicity, less toxic 
DMARDs are being evaluated to replace 
it for treatment of other rheumatic dis-
eases. A recent randomized controlled trial 
of 100 patients with antineutrophil cyto-
plasmic antibody–associated systemic vas-
culitis showed methotrexate may be able 
to replace cyclosporine for both induction 
of remission (methotrexate=89.8% vs cy-
closporine=93.5%; P=.041) and mainte-
nance of remission (69.5% vs 46.5% at 
18 months; P=.023).10 
Initial trials on other rheumatic dis-
eases have been small and have had var-
ied results. There are mixed studies on the 
effectiveness of adding methotrexate to 
corticosteroids for giant cell arteritis.11,12 
There has been no evidence of effi-
cacy for the new TNF antagonists in ei-
ther a small study on Sjögren’s syndrome 
(n=14)13 or a larger study on Wegener’s 
granulomatosis (n=180).14 
The studies for use of DMARDs in lu-
pus or scleroderma are of limited quality.
A review of 54 
studies found 
NSAIDs are still 
the preferred first-
line therapy for 
psoriatic arthritis
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Recommendations from others
The Italian Society for Rheumatology 
consensus guidelines recommends TNF 
antagonists be considered in active pso-
riatic arthritis resistant to (a) NSAIDs, 
(b) at least 2 local steroid injections, and 
(c) at least 2 conventional DMARDs 
for patients with peripheral arthritis or 
enthesitis. They also recommend TNF 
antagonists be considered for psoriatic 
spondylitis resistant to NSAIDs.15
The Assessment in Ankylosing Spon-
dylitis (ASAS) International Working 
Group and the European League Against 
Rheumatism (EULAR) recommendations 
for the treatment of ankylosing spondyli-
tis, based on a systematic review of the lit-
erature and expert opinion, indicate that: 
•  There is good evidence for using 
NSAIDs and COX-2 inhibitors for 
symptomatic treatment.
•  Conventional DMARDs are not 
well supported. 
•  TNF antagonists show a large ben-
efit in both pain and function. 
The ASAS/EULAR recommendation 
indicate that there is no evidence that any 
of these treatments actually modify the 
disease progression.16  n
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